Jenny Leeds is a healthcare investor with Counterpoint Global, a division of Morgan Stanley Investment Management. Her career includes roles in equity research, focusing on biotechnology at Bank Of America Merrill Lynch, and as a biotech analyst at Perceptive Advisors.

Prior to her investment career, Leeds was a PhD Candidate in Cancer biology & Immunology at Memorial Sloan Kettering Cancer Center.